LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Elitra, whose assets were acquired by Merck in 2004, was an antimicrobial functional genomics company that focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms.
Elitra Phramaceuticals
San Diego, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.